Experience
Brii Biosciences Announces Agreements to Acquire VBI Vaccines’ IP Rights in BRII-179
February 14, 2024
Cooley advised Brii Biosciences on its agreements with VBI Vaccines (NASDAQ: VBIV) to ensure expansion and control of future clinical and commercial supplies of BRII-179, a late-stage clinical asset in Brii Bio’s hepatitis B virus functional cure portfolio. With operations in major biotechnology centers in the US and China, Brii Bio (HKSE: 2137) is a Hong Kong Stock Exchange-listed biotechnology company developing therapies to improve patient health and choice across diseases with high unmet needs.
Related contacts
Related Practices & Industries
Gracell Biotechnologies Agrees to Acquisition by AstraZeneca for up to $1.2 Billion
December 26, 2023
Cooley advised Gracell Biotechnologies, a global clinical-stage biopharmaceutical company dedicated to developing innovative cell therapies for the treatment of cancer and autoimmune diseases, on its definitive agreement to be acquired by AstraZeneca.
Related contacts
Related Practices & Industries
TriSalus Life Sciences Completes Merger With MedTech Acquisition Corporation
August 16, 2023
Cooley advised TriSalus Life Sciences, an oncology company with a focus on treatments for patients with liver and pancreatic tumors, on its merger with MedTech Acquisition Corporation.
Related contacts
Related Practices & Industries
Veritone Acquires Broadbean
June 5, 2023
Cooley is advising Veritone, an artificial intelligence company, on its acquisition of Broadbean for $52 million.
Related contacts
Related Practices & Industries
NKGen Biotech Announces Merger With Graf Acquisition Corp. IV
April 28, 2023
Cooley advised NKGen Biotech, a clinical-stage biotechnology company, on its business combination agreement with special purpose acquisition company Graf Acquisition Corp. IV – a combination that will result in NKGen becoming a publicly listed company.
Related contacts
Related Practices & Industries
Related news and events
Brii Biosciences Announces Agreements to Acquire VBI Vaccines’ IP Rights in BRII-179
Gracell Biotechnologies to be Acquired by AstraZeneca for up to Approximately $1.2 Billion
TriSalus Life Sciences Completes Merger With MedTech Acquisition Corporation
Admissions & credentials
California